Published in Genome Med on March 30, 2012
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. PLoS Negl Trop Dis (2015) 1.42
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today (2013) 1.24
A survey of current trends in computational drug repositioning. Brief Bioinform (2015) 1.18
DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis (2014) 1.05
Comprehensive prediction of drug-protein interactions and side effects for the human proteome. Sci Rep (2015) 0.99
From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J (2013) 0.98
Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience (2013) 0.94
Toward more realistic drug-target interaction predictions. Brief Bioinform (2014) 0.92
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio (2015) 0.92
Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. J Mark Access Health Policy (2013) 0.85
A systems framework for vaccine design. Curr Opin Immunol (2013) 0.83
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun (2016) 0.79
Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth. mSphere (2016) 0.78
Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga. Curr Pharmacogenomics Person Med (2013) 0.77
Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. Am J Med (2015) 0.76
Repurposing medicinal compounds for blood cancer treatment. Ann Hematol (2015) 0.76
Data integration to prioritize drugs using genomics and curated data. BioData Min (2016) 0.75
Ultra-rare Disease and Genomics-Driven Precision Medicine. Genomics Inform (2016) 0.75
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva. Dis Model Mech (2016) 0.75
Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery. BMC Genomics (2016) 0.75
Optimal drug prediction from personal genomics profiles. IEEE J Biomed Health Inform (2015) 0.75
The purpose of repurposing. Oncotarget (2017) 0.75
DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome. Sci Rep (2016) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res (2006) 44.35
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
The protein kinase complement of the human genome. Science (2002) 35.36
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res (2007) 17.46
Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57
DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res (2006) 15.19
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Drug target identification using side-effect similarity. Science (2008) 9.24
Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med (2011) 9.03
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Drug discovery: a historical perspective. Science (2000) 8.15
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57
Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov (2011) 7.47
Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov (2009) 7.01
Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16
New uses for old drugs. Nature (2007) 5.86
Statistical practice in high-throughput screening data analysis. Nat Biotechnol (2006) 5.85
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Global mapping of pharmacological space. Nat Biotechnol (2006) 4.99
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A (2010) 4.35
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov (2004) 4.31
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov (2010) 4.02
Adopting orphan drugs--two dozen years of treating rare diseases. N Engl J Med (2006) 3.98
SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res (2007) 3.82
The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med (2011) 3.80
Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A (2007) 3.37
ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics (2008) 3.35
Preparing for precision medicine. N Engl J Med (2012) 3.34
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov (2011) 2.73
PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet (2007) 2.65
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov (2006) 2.64
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60
Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today (2006) 2.59
Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform (2011) 2.52
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol (2009) 2.35
TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res (2006) 2.26
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21
Drug discovery: playing dirty. Nature (2005) 2.12
Imatinib as a paradigm of targeted therapies. Adv Cancer Res (2004) 2.11
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci (2010) 2.06
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem (2008) 1.88
Cellular targets of gefitinib. Cancer Res (2005) 1.87
The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst (2009) 1.85
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol (2010) 1.77
Screening in a spirit haunted world. Drug Discov Today (2006) 1.75
Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins (2001) 1.73
PubChem as a source of polypharmacology. J Chem Inf Model (2009) 1.68
Vemurafenib. Nat Rev Drug Discov (2011) 1.68
The value of drug repositioning in the current pharmaceutical market. Drug News Perspect (2009) 1.51
Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol (2009) 1.49
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther (2007) 1.42
Drug repositioning for orphan diseases. Brief Bioinform (2011) 1.37
Asthma: a syndrome composed of heterogeneous diseases. Ann Allergy Asthma Immunol (2008) 1.21
High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res (2009) 1.20
Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med (2011) 1.17
Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform (2011) 1.17
A computational approach to finding novel targets for existing drugs. PLoS Comput Biol (2011) 1.17
Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform (2011) 1.14
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res (2009) 1.13
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics (2002) 1.08
BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome. Nucleic Acids Res (2009) 1.07
International group seeks to dispel incontinence "taboo". JAMA (1998) 1.07
Crizotinib. Nat Rev Drug Discov (2011) 1.05
Drug discovery: How melanomas bypass new therapy. Nature (2010) 1.05
Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol (2006) 1.04
Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol (2011) 1.02
Crizotinib--latest champion in the cancer wars? N Engl J Med (2010) 1.01
The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes (2007) 1.01
Computational approaches for drug repositioning and combination therapy design. J Bioinform Comput Biol (2010) 1.00